Condition
Group B Strep Infection
Total Trials
6
Recruiting
1
Active
2
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 15/100
Termination Rate
0.0%
0 terminated out of 6 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
17%
1 trials in Phase 3/4
Results Transparency
100%
2 of 2 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 3 (1)
Trial Status
Completed2
Unknown2
Active Not Recruiting1
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT07562061RecruitingPrimary
mulTiplex Immunoassay qualiTy assuRance Panel
NCT04721912Phase 3CompletedPrimary
Group B Streptococcus Response After Probiotic Exposure
NCT04549220Active Not Recruiting
Serosurveillance Study of Maternally Derived Anti-GBS Antibody
NCT04653948Unknown
Maternal, Neonatal and Infant Outcomes at Kawempe National Referral Hospital
NCT04732026Unknown
Serocorrelate of Protection Against GBS (PREPARE WP3)
NCT03807245Phase 1CompletedPrimary
Group B Streptococcus Vaccine in Healthy Females
Showing all 6 trials